vs
Side-by-side financial comparison of 4D Molecular Therapeutics, Inc. (FDMT) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
Twist Bioscience Corp is the larger business by last-quarter revenue ($103.7M vs $85.1M, roughly 1.2× 4D Molecular Therapeutics, Inc.). 4D Molecular Therapeutics, Inc. runs the higher net margin — 22.8% vs -29.4%, a 52.2% gap on every dollar of revenue. On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs 16.9%). 4D Molecular Therapeutics, Inc. produced more free cash flow last quarter ($28.5M vs $-34.8M).
4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
FDMT vs TWST — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $85.1M | $103.7M |
| Net Profit | $19.4M | $-30.5M |
| Gross Margin | — | 52.0% |
| Operating Margin | 17.3% | -31.7% |
| Net Margin | 22.8% | -29.4% |
| Revenue YoY | 8508900.0% | 16.9% |
| Net Profit YoY | 139.1% | 3.4% |
| EPS (diluted) | $0.43 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $85.1M | $103.7M | ||
| Q3 25 | $90.0K | — | ||
| Q2 25 | $15.0K | — | ||
| Q1 25 | $14.0K | — | ||
| Q4 24 | $1.0K | — | ||
| Q3 24 | $3.0K | — | ||
| Q2 24 | $5.0K | — | ||
| Q1 24 | $28.0K | — |
| Q4 25 | $19.4M | $-30.5M | ||
| Q3 25 | $-56.9M | — | ||
| Q2 25 | $-54.7M | — | ||
| Q1 25 | $-48.0M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-43.8M | — | ||
| Q2 24 | $-35.0M | — | ||
| Q1 24 | $-32.4M | — |
| Q4 25 | — | 52.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 17.3% | -31.7% | ||
| Q3 25 | -67983.3% | — | ||
| Q2 25 | -396373.3% | — | ||
| Q1 25 | -383007.1% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -1704400.0% | — | ||
| Q2 24 | -849120.0% | — | ||
| Q1 24 | -136200.0% | — |
| Q4 25 | 22.8% | -29.4% | ||
| Q3 25 | -63195.6% | — | ||
| Q2 25 | -364386.7% | — | ||
| Q1 25 | -342657.1% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -1461433.3% | — | ||
| Q2 24 | -699060.0% | — | ||
| Q1 24 | -115717.9% | — |
| Q4 25 | $0.43 | $-0.50 | ||
| Q3 25 | $-1.01 | — | ||
| Q2 25 | $-0.98 | — | ||
| Q1 25 | $-0.86 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.79 | — | ||
| Q2 24 | $-0.63 | — | ||
| Q1 24 | $-0.66 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $402.7M | $197.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $505.7M | $456.1M |
| Total Assets | $566.7M | $638.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $402.7M | $197.9M | ||
| Q3 25 | $305.1M | — | ||
| Q2 25 | $293.2M | — | ||
| Q1 25 | $321.4M | — | ||
| Q4 24 | $424.9M | — | ||
| Q3 24 | $501.9M | — | ||
| Q2 24 | $541.9M | — | ||
| Q1 24 | $525.9M | — |
| Q4 25 | $505.7M | $456.1M | ||
| Q3 25 | $369.0M | — | ||
| Q2 25 | $420.9M | — | ||
| Q1 25 | $469.7M | — | ||
| Q4 24 | $510.6M | — | ||
| Q3 24 | $552.9M | — | ||
| Q2 24 | $588.3M | — | ||
| Q1 24 | $600.6M | — |
| Q4 25 | $566.7M | $638.1M | ||
| Q3 25 | $424.0M | — | ||
| Q2 25 | $473.6M | — | ||
| Q1 25 | $515.7M | — | ||
| Q4 24 | $560.4M | — | ||
| Q3 24 | $604.0M | — | ||
| Q2 24 | $620.1M | — | ||
| Q1 24 | $629.9M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.6M | $-24.8M |
| Free Cash FlowOCF − Capex | $28.5M | $-34.8M |
| FCF MarginFCF / Revenue | 33.5% | -33.5% |
| Capex IntensityCapex / Revenue | 0.1% | 9.6% |
| Cash ConversionOCF / Net Profit | 1.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-109.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.6M | $-24.8M | ||
| Q3 25 | $-46.5M | — | ||
| Q2 25 | $-43.4M | — | ||
| Q1 25 | $-47.8M | — | ||
| Q4 24 | $-134.6M | — | ||
| Q3 24 | $-29.4M | — | ||
| Q2 24 | $-30.2M | — | ||
| Q1 24 | $-29.1M | — |
| Q4 25 | $28.5M | $-34.8M | ||
| Q3 25 | $-46.6M | — | ||
| Q2 25 | $-43.4M | — | ||
| Q1 25 | $-48.4M | — | ||
| Q4 24 | $-138.4M | — | ||
| Q3 24 | $-31.2M | — | ||
| Q2 24 | $-30.6M | — | ||
| Q1 24 | $-29.8M | — |
| Q4 25 | 33.5% | -33.5% | ||
| Q3 25 | -51765.6% | — | ||
| Q2 25 | -289620.0% | — | ||
| Q1 25 | -345635.7% | — | ||
| Q4 24 | -13837100.0% | — | ||
| Q3 24 | -1038966.7% | — | ||
| Q2 24 | -611840.0% | — | ||
| Q1 24 | -106421.4% | — |
| Q4 25 | 0.1% | 9.6% | ||
| Q3 25 | 101.1% | — | ||
| Q2 25 | 440.0% | — | ||
| Q1 25 | 4507.1% | — | ||
| Q4 24 | 378600.0% | — | ||
| Q3 24 | 59266.7% | — | ||
| Q2 24 | 6980.0% | — | ||
| Q1 24 | 2535.7% | — |
| Q4 25 | 1.47× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FDMT
Segment breakdown not available.
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
